Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
AssigneeProtab Ltd.
InventorsYaakov Naparstek, Eli Moallem
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
Claims5
A method for treating an immune-related disorder other than asthma in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of
- a compound that interacts with Adenylyl Cyclase-Associated Protein (CAP1), wherein said compound is an anti-CAP1 antibody that specifically recognizes and binds CAP1, and increases IL-10, with the proviso that the antibody is not any of the polyclonal, monoclonal, chimeric or humanized anti-peptide-6 antibodies,
- and wherein said subject in need is other that a subject having asthma.
A method for treating an immune-related disorder other than asthma in a subject in need thereof, comprising the step of administering to said subject a therapeutically effective amount of an anti-Adenylyl Cyclase-Associated Protein (CAP1) antibody that specifically recognizes and binds CAP1, or a composition comprising the same, wherein said antibody increases IL-10, thereby modulating the balance between Th1/Th2 in said subject towards the Th2 anti-inflammatory response, with the proviso that the antibody is not any of the polyclonal, monoclonal, chimeric or humanized anti-peptide-6 antibodies, and wherein said subject in need is other than a subject having asthma.
A method for increasing the levels of IL-10 (Interleukin-10) in a subject suffering from an immune-related disorder other than asthma, comprising the step of administering to said subject a therapeutically effective amount of an anti-CAP1 antibody that specifically recognizes and binds CAP1, or a composition comprising the same, with the proviso that the antibody is not any of the polyclonal, monoclonal, chimeric or humanized anti-peptide-6 antibodies.
Dependencies are inferred from the claim text.